Abstract:To achieve pyroptosis of tumor cells, engineered cellular nanovesicles presenting TRAIL (NVTRAIL) are developed to trigger the upregulation of cleaved caspase‐3, and chemotherapeutic agent mitoxantrone (MTO) is employed to enhance GSDME expression. Consequently, MTO@NVTRAIL are able to convert cancer cells from apoptosis into pyroptosis, effectively inhibiting the tumor growth and metastasis in primary tumor. Pyroptosis, a highly inflammatory form of programmed cell death, has emerged as a promising target for cancer immunotherapy. However, in the context of pyroptosis execution, while both caspase‐3 and GSDME are essential, it is noteworthy that GSDME is frequently under‐expressed in cold tumors. To overcome this limitation, engineered cellular nanovesicles (NVs) presenting TRAIL on their membranes (NVTRAIL) are developed to trigger the upregulation of cleaved caspase‐3. When strategically combined with the chemotherapeutic agent mitoxantrone (MTO), known for its ability to enhance GSDME expression, MTO@NVTRAIL can convert cancer cells from apoptosis into pyroptosis, inhibit the tumor growth and metastasis successfully in primary tumor. The microparticles released by pyroptotic tumor cells also exhibited certain cytotoxicity against other tumor cells. In addition, tumor cells exposed to the combination treatment of MTO@NVTRAIL in vitro have also demonstrated potential utility as a novel form of vaccine for cancer immunotherapy. Flow analysis of the tumor microenvironment and draining lymph nodes reveals an increased proportion of matured dendritic cells and activation of T cells. In summary, the research provided a reference and alternative approach to induce cancer pyroptosis for clinical antitumor therapy based on engineered cellular nanovesicles and chemotherapy.

Bioengineering of BRAF and COX2 inhibitor nanogels to boost the immunotherapy of melanoma via pyroptosis

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis

Codelivery of afuresertib and celecoxib by IL4RPep-1-targeting nanoparticles for effective treatment against melanoma

Engineered Nanogels Simultaneously Implement HDAC Inhibition and Chemotherapy to Boost Antitumor Immunity Via Pyroptosis

Enhancing cell pyroptosis with biomimetic nanoparticles for melanoma chemo-immunotherapy

Co‐delivery Nano System of MS‐275 and V‐9302 Induces Pyroptosis and Enhances Anti‐Tumor Immunity Against Uveal Melanoma

Strategies of Combination Drug Delivery for Immune Checkpoint Blockades.

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy

MAPK‐Targeted Drug Delivered by a Ph‐sensitive MSNP Nanocarrier Synergizes with PD‐1 Blockade in Melanoma Without T‐Cell Suppression

Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade

Inflammation-Driven Nanohitchhiker Enhances Postoperative Immunotherapy by Alleviating Prostaglandin E2-Mediated Immunosuppression

Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy

Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment

Programmed albumin nanoparticles regulate immunosuppressive pivot to potentiate checkpoint blockade cancer immunotherapy

Synergistic Therapy of Melanoma by Co-Delivery of Dacarbazine and Ferroptosis-Inducing Ursolic Acid Using Biomimetic Nanoparticles

A platinum@polymer-catechol nanobraker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance

Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma

Mitoxantrone Combined with Engineered TRAIL‐Nanovesicles for Enhanced Cancer Immunotherapy Via Converting Apoptosis into Pyroptosis

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD‐L1 Expression for Circumventing Immune Resistance of Cancer